Leerink raised the firm’s price target on Neurocrine to $135 from $125 and keeps an Outperform rating on the shares. The readout from the pediatric study of crinecerfont in congenital adrenal hyperplasia was the best-case scenario, the analyst tells investors in a research note. It was clear from the KOL’s commentary on the call that this will be a game-changing therapy for both adults and children with CAH, the firm adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine price target raised to $157 from $152 at Baird
- Neurocrine price target raised to $165 from $160 at Oppenheimer
- Neurocrine price target raised to $150 from $146 at H.C. Wainwright
- Neurocrine Stock (NASDAQ:NBIX) Gains on Positive Pediatric Phase 3 Results
- Neurocrine’s crinecerfont meets primary and secondary endpoints in Phase 3 trial